Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257 is registered in ClinicalTrials.gov with ProQR Therapeutics as lead sponsor.

NCT NCT03780257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03780257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Lead sponsor
ProQR Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
March 6, 2019
Completion date
October 14, 2021
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

deaf blind, eye diseases, eye diseases, hereditary, eye disorders congenital, retinal disease, retinitis pigmentosa, usher syndrome type 2, vision disorders